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KEY GENETIC ALTERATIONS
Telomere Maintanance 
Genes: TERT
Cumulative frequency: 20%-60% 
WNT/β-Catenin
Genes: CTNNB1, AXIN1/2, APC
Cumulative frequency: 2%-33%
Cell Cycle
Genes: TP53, CKN2A/B, CCND/E1, CDKs, RB1
Cumulative frequency: 4%-35%
Apoptosis
Genes: TNFRSF10A/B, TRADD, CASP3/9, XIAP
Cumulative frequency: 8%-20%
Epigenetic Modifiers
Genes: ARID1A, ARID2, MLL genes
Cumulative frequency: 10%-24%
Proliferation
Genes: FGF19, RPS6KA, IRF2, KRAS
Cumulative frequency: 2%-15%
Immune Response
Genes: IL6R, IL20, IL6, JAK1
Cumulative frequency: 2%-26%
Oxidative Stress Regulation
Genes: NFEL2, KEAP1
Cumulative frequency: 6%-8%
CLINICAL PROGRESSION OF LIVER CANCER CELL TYPES OF ORIGIN FOR HCC
D
iff
er
en
ti
at
io
n
S
te
m
n
es
s
PROGNOSTIC CLASSIFICATION
EMERGING MOLECULAR TARGETS
BCLC STAGING & THERAPY
CHALLENGES & OUTLOOK
Poor Outcome
Healthy
liver
Chronic
injury
Cirrhosis HCC
Stem
cell
Cancer
stem cell
Aggresive
phenotype
Intermediate
phenotype
Benign
phenotype
Bulk
tumor cells
Bipotential
progenitor
Hepatocyte/
Cholangiocyte
C
lin
ic
al
/
M
o
rp
ho
lo
g
ic
al
 fe
at
ur
es
M
o
le
cu
la
r 
fe
at
ur
es
Favorable Outcome
Curative treatments
HCC
suspected
Palliation
Epigenetics
Proliferation and Survival
Tivantinib, cixutumumab,
erlotinib, everolimus, selumetinib
Control of gene expression:
Activation of tumor suppressors
Repression of oncogenes
Resminostat, vorinostat,
belinostat, zebularine
Stemness
Dedifferentiation, progression 
and metastatic properties
12-AA peptide, resminostat,
γ-secretase inhibitors
Angiogenesis
Median OS: >60 mo 20 mo 11 mo ~3 mo
Sorafenib, brivanib,
sunitinib, regorafenib
ECOG >2
Poor liver function
Poor differentiation
CK19 positive
Larger tumors
Vascular invasion
Extrahepatic spread
Genomic instability
Telomerase reactivation 
Loss of 8p
Global hypomethylation
Low miR-122
High miR-517a
Stemness features:
EpCAM, SALL4
High Nault 5-gene score
Adverse subclass:
G1-G3, S1-2, proliferation,
HA subtype
Adverse metabolic profile:
stearoyl-CoA-desaturase
activity, palmitate signaling
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mTOR, IGF, MYC, AKT,
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HCC develops on the basis of a predisposing 
liver disease that causes a chronically altered 
microenvironment.
HCC is characterized by phenotypic and 
molecular heterogeneity reecting a diverse 
cellular origin.
Biopsies are not mandatory to establish the 
diagnosis. However, biopsies are of utmost 
importance for molecular classication and 
individualized therapeutic approaches.
Our understanding of (epi)genetic 
pathophysiology is incomplete.
The most common genetic alterations affect 
hTERT, β-catenin, and p53. No clear evidence 
for oncogene addiction has been demonstrated.
In clinical routine, liver function frequently limits 
therapeutic options.
Recurrence rate is high despite curative 
therapeutic intentions.
There is an unmet need for new therapies and 
improved understanding of cancer biology.
Novel innovative therapeutic strategies involve 
targeting of stem cell features as well as 
immune response.
Contrast MRI imaging illustrating 
typical hyperenhancement (wash-in) 
in the arterial phase followed by 
wash-out in the venous phase.
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Hepatocellular carcinoma (HCC) is the sixth most common cancer globally, with a prevalence of around 600,000 people worldwide. HCC incidence has risen steadily over the last 
20 years in western countries such as the United States, Europe, and Japan, predominantly due to increased rates of chronic Hepatitis C virus infections, alcohol abuse, obesity, 
and type 2 diabetes. As a result, HCC is one of the most rapidly growing cancers in these countries. The number of deaths is proportional to the global incidence, which highlights 
the aggressive tumor biology and lack of effective therapies. These observations manifest the fact that liver cancer is a major health problem in the United States and Europe and 
highlight the critical need for improved understanding and better treatment options for this deadly disease.
Sequential Evolution and Cell of Origin
Hepatocarcinogenesis is a complex multistep process driven by chronic hepatitis that alters the hepatic microenvironment. The earliest dysplastic lesions generally develop 
in cirrhotic livers. Chronic inflammation and liver cirrhosis predispose HCC development by creating an adverse protumorigenic microenvironment that generates pro-oncogenic 
(epi)genetic changes.
Accumulating evidence indicates that only a subpopulation of cells within liver cancer harbors genuine tumorigenic potential. While the existence of cells with self-renewing 
capacity in HCC is well supported, the origin of these cells remains uncertain. Experimental evidence suggests that any cell of the hepatic lineage (i.e., hepatocytes/cholangio-
cytes, progenitor cells, stem cells) can acquire stem cell properties and become a cancer stem cell (CSC) upon acquiring (epi)genetic alterations. However, hepatic CSCs are 
clearly heterogeneous and may therefore contribute to the observed morphological and biological heterogeneity characteristic of HCC. The CSCs not only initiate HCC, but also 
drive distant metastasis and relapse after therapy, thereby establishing CSCs as important therapeutic targets.
Genetic Alterations and Key Pathways
The multistep sequence of epigenetic and genetic alterations in liver cancer pathogenesis disrupts core cellular processes such as proliferation, cell death, and genome 
maintenance. In addition, oncogenic pathways and molecules associated with stemness, angiogenesis, and immune response are changed in HCC due to aberrant signaling 
downstream of pathways orchestrated by p53, WNT, b-Catenin, MYC, and ErbB family proteins. Therefore, the goal of therapeutic approaches in HCC is the specific targeting 
of these signaling pathways.
The advent of sophisticated next-generation sequencing technologies has allowed detailed genetic mapping of the liver cancers. Similar to the phenotypic heterogeneity of 
HCC, the landscape of molecular alterations in HCC is quite extensive. The average mutational burden varies substantially across different tumors and ranges from five to 121 
mutations. Unlike other solid tumors (such as in lung, breast, or colon cancers), an important hallmark of HCC is the absence of clear addiction to an oncogene; this impedes 
the development of targeted therapies. However, highly recurrent somatic mutations are found in genes products in p53 and Wnt/b-Catenin pathways. Other frequently altered 
genes include those involved in epigenetic modification, proliferation, immune response, and oxidative stress response. Interestingly, among the most prominent and earliest 
changes present in HCC are genetic changes in the TERT promoter, which is observed in up to 60% of advanced HCC cases. Among the future challenges will be the identi-
fication of druggable mutations in individual HCCs (such as JAK1 activating mutations observed in up to 10% of HCCs), which might provide an option for novel individualized 
therapeutic interventions.
Prognostic Classification and Staging
Over the last decade, several phenotypic and molecular HCC hallmarks, which are associated with different prognoses, have been identified. However, the application of 
these features in clinical settings has so far been limited. A promising prognostic classification includes a newly developed 5-gene score based on combined expression of HN1, 
RAN, RAMP3, KRT19, and TAF9 that might provide an important step for efficient translational studies. Prospective validation of the score is currently under way.
Patients at risk for HCC development should be screened by abdominal ultrasound every 6 months. The diagnosis HCC can be accurately established by modern imaging 
techniques such as contrast-enhanced CT or MRI. Once the diagnosis is established, HCCs can be classified according to the Barcelona Clinic Liver Cancer (BCLC) staging 
classification. The BCLC is widely accepted in clinical practice; it is the first staging that links liver disease stage to a specific treatment strategy and corresponding survival 
outlook for patients. Liver transplantation and resection are effective therapeutic options at early stages, but more than 70% of HCC patients present with incurable stages.
Emerging Therapies, Challenges, and Outlook
Therapeutic approaches involve the direct targeting of relevant as well as druggable signaling pathways by using a variety of receptor tyrosine kinase inhibitors (RTKi). Several 
preclinical studies and ongoing clinical trials have shown that targeting of universal oncogenic features such as proliferation and angiogenesis by sequential or concomitant 
inhibition of overlapping downstream signaling pathways might be an effective treatment strategy for HCC. Other highly innovative approaches involve targeting HCC-specific 
characteristics related to immune modulation, epigenetic modifications, and stemness.
Liver cancer is the second most lethal cancer worldwide. The phenotypic and molecular heterogeneity of HCC as well as underlying associated chronic inflammatory liver 
diseases have limited therapeutic options and progress. To date, the RTKi Sorafenib is the only approved treatment for advanced HCCs. Recently, several clinical phase III tri-
als have failed to demonstrate improved overall survival in HCC patients, indicating an unmet need for novel therapeutic strategies. Achieving this goal will require mandatory 
biopsies and application of next-generation sequencing technologies for molecular analyses. Implementation of recent translational genomic discoveries into routine clinical 
practice will likely improve the identification of relevant clinical HCC subclasses that might benefit from specific therapies.
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